According to the molecular docking data, tideglusib, which is designed for the treatment of AD [42] and progressive supranuclear palsy (PSP), bound irreversibly to the non-ATP-competitive GSK-3β site [43] (Figure 7). This evidence concerns the gene GSK3B and progressive supranuclear palsy.